Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden Anstalt des öffentlichen Rechts des Freistaates Sachsen
Universitätsklinikum Carl Gustav Carus
ZKN Logo
  • The Center
    • Multiple Sclerosis Center Dresden
      • Patient Information
      • Contact MSC
      • Physicians & Nurses
      • Study Team
      • Neuropsychology
    • Mobility Center
      • The Mobility Center
      • Walking Assessment
      • Jump Assessment
      • DIERS
      • EMIQ
      • Projects
    • Neuroimmunological Laboratory
      • The NIL
      • Neurofilament light chain
    • Autonomic & Neuroendocrinological Functional Laboratory
      • The ANF
      • ANF Assessment
    • MS Living Lab
    • Management & Science
      • Team Management & Science
      • Projects
      • eHealth & Analytics
        • MSDS 3D
        • MSDS Clinic & Practice
        • MS-HRS
        • MTRS
      • Multiple Sclerosis Management
  • Aktuelles
    • Neuigkeiten
    • Publikationen
    • Veranstaltungen
      • Adventssymposium
      • Multiple Sklerose 360°
      • Welt-MS-Tag 2021
    • Doktorarbeiten
    • Jobs
    • Kontakt
    • Spenden
  • Podcasts & Newsletter
    • Newsletter
    • Patienten-Podcast
    • Ärzte-Podcast
    • Neurovision
    • Immune cell calender 25
    • Sherlock-MS-Blog
  • Studien
    • Interventionelle Studien
    • B-SHUTTLE
    • Nicht-interventionelle Studien
    • MS PATHS
    • Konectom
    • Sprachanalyse
MS 360 Grad
EnglishEnglish
DeutschDeutsch
EnglishEnglish

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab

MS Treatments

Jahr

Publikationsjahr
2020

Autoren

Autorenliste der Publikation
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Cornelissen C, Ettle B; PANGAEA Study Group.

Verlag

Publisher-Information
Mult Scler Relat Disord. 2020 Apr;39:101893.

Link

Zur Publikation (externer Server)
https://doi.org/10.1016/j.msard.2019.101893

Tags

Forschungsthemen
Multiple SkleroseMS Behandlung
Treatments2020

  • Ziemssen T, Centonze D. Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing. Mult Scler. 2025 Jun;31(7):751-753. doi: 10.1177/13524585251346658. Epub 2025 Jun 14. PMID: 40515640.

    MS Treatments
    Jahr
    2025

  • CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

    MS Treatments
    Jahr
    2025

  • RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis

    MASC
    Jahr
    2025

  • Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

    MASC
    Jahr
    2025

  • Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs

    NIL
    Jahr
    2025
  • Start
  • Aktuelles
  • Publikationen
  • MS Treatments
  • Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab
Uniklinikum Carl Gustav Carus
UKD Neurologie
TU Dresden
Impressum & Datenschutz
MSZ @ Facebook
MSZ @ Google
ZKN @ Youtube

© 2025
Universitätsklinikum C.G. Carus Dresden an der Technischen Universität Dresden